Tarveda Therapeutics

Developer of pentarin miniature drug conjugate medicines intended to make a difference in the treatment of patients with solid tumor malignancies. The company's platform provides a lead drug candidate that releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 expressing neuroendocrine, small cell lung, and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

New Enterprise Associates

🏥 Healthcare